GHRP-6 vs GHRP-2: Comparing the Older Secretagogues

GHRP-6 and GHRP-2 are part of an older generation of growth-hormone-releasing peptides, synthetic compounds designed to prompt the pituitary to release its own growth hormone rather than supplying GH directly. GHRP-6 was the first synthetic hexapeptide of this kind, discovered by the American endocrinologist Cyril Bowers from work on enkephalin analogs; GHRP-2 followed. They’re usually discussed together because they’re close cousins with overlapping behavior and a shared history, and that history helps explain why later peptides were developed at all.

This is a comparison, not an endorsement. Both sit in a research and consumer gray zone with limited modern human trial support, and neither is an approved therapy for muscle, fat loss, or anti-aging.

How they’re similar, and where they differ

Both act on the same target: the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a), expressed in the hypothalamus and pituitary. Both trigger GH release from pituitary somatotrophs. The same receptor activity that releases GH also reaches the lactotroph and corticotroph cells: in human studies of this peptide class, GH secretagogues raised not only GH but also prolactin, ACTH, and cortisol. That hormonal “spillover” is a class feature, not a footnote.

The most-cited practical difference (that GHRP-6 drives noticeably more appetite than GHRP-2, while GHRP-2 is the slightly stronger GH releaser) is widely repeated but rests mostly on small, older studies and a great deal of anecdote rather than head-to-head modern trials. Treat it as a rough characterization, not a settled fact.

The reliably documented part is acute hormone release: these peptides pulse GH, and they also nudge prolactin, ACTH, and cortisol. The downstream body-composition claims are far less established.

Quick comparison

	GHRP-6	GHRP-2
Receptor	GHS-R1a (ghrelin)	GHS-R1a (ghrelin)
GH release	Yes, dose-dependent	Yes; often described as somewhat stronger
Appetite	Strong stimulation (its defining trait)	Usually less
Other hormones	Can raise cortisol/prolactin	Can raise cortisol/prolactin

Why newer options replaced them

The trajectory of this field is partly a story of refining away inconvenient side effects. The appetite stimulation of GHRP-6, the cortisol and prolactin co-release, and the desire for cleaner, more selective GH release all motivated later compounds (such as ipamorelin) designed to keep the GH-releasing action while trimming the hormonal noise.

That said, “newer” doesn’t automatically mean “better established.” Much of this entire category remains thin on long-term human safety and efficacy data, regardless of generation.

A measured read

GHRP-6 and GHRP-2 are useful mainly as a window into how this peptide class works and why it evolved. The acute, multi-hormone release is genuine and documented. The leap from a GH pulse to meaningful changes in muscle, fat, or recovery is poorly supported, and the side-effect profile (appetite, cortisol, prolactin) is a real consideration rather than a footnote.

The takeaway

The practical difference between these two is mostly appetite, with GHRP-6 the hungrier of the pair; both reliably pulse GH and both co-release stress and lactation hormones, which is mostly why later peptides displaced them. The honest limit is that the well-documented part is acute hormone release, while the desirable downstream outcomes remain weakly evidenced for the whole class.

Sources

• Arvat et al., Endocrine Activities of Ghrelin and Hexarelin in Humans, J Clin Endocrinol Metab (2001)
• GHRP-6 and related secretagogue peptides review, Integrative Molecular Medicine (2016)